Journal article
RNA sequencing to predict response to neoadjuvant anti-HER2 therapy a secondary analysis of the NeoALTTO randomized clinical trial
D Fumagalli, D Venet, M Ignatiadis, HA Azim, M Maetens, F Rothé, R Salgado, I Bradbury, L Pusztai, N Harbeck, H Gomez, TW Chang, MA Coccia-Portugal, S Di Cosimo, E De Azambuja, L De La Peña, P Nuciforo, JC Brase, J Huober, J Baselga Show all
JAMA Oncology | AMER MEDICAL ASSOC | Published : 2017
Abstract
IMPORTANCE In neoadjuvant trials, treatment of human epidermal growth factor receptor 2 (HER2) -positive breast cancers with dual HER2 blockade resulted in increased pathologic complete response (pCR) rates compared with each targeted agent alone. Amplification and/or overexpression of HER2 currently remains the only biomarker for therapeutic decisions, but it is insufficient to explain the heterogeneous response to anti-HER2 agents. OBJECTIVE To investigate the ability of clinically and biologically relevant genes and gene signatures (GSs) measured by RNA sequencing to predict the efficacy of anti-HER2 agents. DESIGN, SETTING, AND PARTICIPANTS The neoadjuvant NeoALTTO trial randomized 455 w..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
The NeoALTTO study and this substudy were sponsored by GlaxoSmithKline; lapatinib is an asset of Novartis AG as of March 2, 2015. Dr Venet's activity is partly supported by a grant of the Region Wallonne.